Scarica l'app Stockscreener
0.1702
4.42%
0.0072
Dopo l'orario di chiusura:
.17
-0.0002
-0.12%
Precedente Chiudi:
$0.163
Aprire:
$0.16
Volume 24 ore:
3.26M
Relative Volume:
0.50
Capitalizzazione di mercato:
$155.11M
Reddito:
$420.00K
Utile/perdita netta:
$-35.84M
Rapporto P/E:
-0.0287
EPS:
-5.9381
Flusso di cassa netto:
$-32.12M
1 W Prestazione:
-14.90%
1M Prestazione:
-56.13%
6M Prestazione:
-88.95%
1 anno Prestazione:
-96.43%
Intervallo 1D:
$0.1455
$0.1736
Intervallo di 1 settimana:
$0.1455
$0.2041
Portata 52W:
$0.1455
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1702 | 155.11M | 420.00K | -35.84M | -32.12M | -5.9381 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Iniziato | Mizuho | Outperform |
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
Kala Pharmaceuticals Inc (27F0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
KALA Bio launches on-premises AI platform for biotech sector - Investing.com
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO, Inc. (KALA) stock price, news, quote and history - Yahoo Finance UK
Kala Bio engages advisor to review clinical assets, AI analytics By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - manilatimes.net
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ... - Caledonian Record
Kala Bio brings in AI-focused adviser to reassess Phase 2 data - Stock Titan
Kala Bio Delays 2025 Annual Report Filing - TipRanks
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Bionic Intelligence Research Agent Now Commercially Live - openPR.com
FinancialContentBionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - FinancialContent
Kala Bio deploys AI research agent for biotech clients By Investing.com - Investing.com South Africa
Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - MarketScreener
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Kala Bio deploys AI research agent for biotech clients - Investing.com India
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - The Manila Times
Kala says its private AI research agent is now live for biotech clients - Stock Titan
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchKala Bio (NASDAQ:K - Benzinga
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
KALA BIO Inc expected to post a loss of $1.44 a shareEarnings Preview - TradingView
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Trading Action: Will KALA BIO Inc stock benefit from M A2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March - MarketBeat
Kala Bio rises on plans to leverage AI - MSN
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
KALA Engages AI Technology for Advancing Psilocybin Drug Development - GuruFocus
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - Investing News Network
Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010 - tipranks.com
Red Light Holland Engages Kala Bio’s Researgency.AI - GlobeNewswire
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - TMX Newsfile
AI to speed testing of psilocybin drug PEX010 for addiction and depression - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Stock Trend Capital Highlights Younet AI’s Exclusive Biotech Partnership with KALA BIO - TipRanks
KALA BIO to launch first commercial AI agent in two weeks - Investing.com Nigeria
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update - MarketBeat
Why Did KALA Stock Surge 25% Today? - Stocktwits
Form 144 KALA BIO For: 12 March By Investing.com - Investing.com Australia
Kala Bio chases 'Palantir for biotech' dream with new AI platform - MSN
Movement Recap: Does Dragonfly Energy Holdings Corp Equity Warrant have consistent dividend growthQuarterly Trade Report & Expert Curated Trade Ideas - baoquankhu1.vn
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
After Hours 11 Mar 2026: KALA BIO (KALA NASDAQ) up 24.16% to $0.36, model sees upside - Meyka
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - The Globe and Mail
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):